	BIG 1-98
Aromatase inhibitor
Breast cancer
Letrozole
Adjuvant therapy
Tamoxifen
	breast cancer
tamoxifen monotherapy
initial therapy
treatment arms
letrozole
tamoxifen
BIG 1
women
hormone-sensitive breast cancer
prior cancer event
primary core analysis
trial
upfront therapy
patients
distant recurrence
monotherapy arms
systemic DFS
analysis
treatment
events
risk
results
DFS
recurrence
adjuvant hormonal therapy
years
tumor
distant site
arms B
time
skeletal events
risk reduction
clinical
additional
significant benefit
primary
monotherapy
higher incidence

